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cific application could be performed,
which would then match the characteris-
tics of the antenna with the protein sol-
der and tissue to best effect wound clo-
sure. An additional area of interest with
potential benefit that remains to be vali-
dated is whether microwave energy can
effectively kill bacteria in and around
the wound. Thus, this may be an effi-
cient method for simultaneously steriliz-
ing and closing wounds.
Using microwave energy to seal
wounds has a number of advantages
over lasers, which are currently in exper-
imental use in some hospitals. Laser tis-
sue welding is unsuitable for emergency
use because its large, bulky equipment
cannot be easily moved between operat-
ing rooms, let alone relocated to field
sites where emergencies often occur. In
addition, this approach is highly de-
pendent on the uniformity and thick-
ness of the protein solder as well as the
surgeon’s skills. In contrast, the use of
microwave energy is highly tolerant of
the thickness of the protein solder, level
of fluids in and around the wound, and
other parameters that can adversely af-
fect the outcome of laser welding. How-
ever, controlling the depth of penetra-
tion of the microwave energy into the
wound is critical for achieving effective
wound sealing without damaging the ad-
jacent tissue. In addition, microspheres
that encapsulate metallic cores could
also be incorporated into the protein
solder to further control the depth of
penetration of the microwave energy.
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This invention is owned by NASA, and a
patent application has been filed. Inquiries
concerning nonexclusive or exclusive license
for its commercial development should be ad-
dressed to the Patent Counsel, Johnson Space
Center, (281) 483-1003. Refer to MSC-
24238-1.
Principles, Techniques, and Applications of 
Tissue Microfluidics 
This technique can be used in the diagnosis of diseases such as cancer. 
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The principle of tissue microfluidics
and its resultant techniques has been
applied to cell analysis. Building mi-
crofluidics to suit a particular tissue
sample would allow the rapid, reliable,
inexpensive, highly parallelized, selec-
tive extraction of chosen regions of tis-
sue for purposes of further biochemical
analysis. Furthermore, the applicability
of the techniques ranges beyond the de-
scribed pathology application. For ex-
ample, they would also allow the posing
and successful answering of new sets of
questions in many areas of fundamental
research. 
The proposed integration of mi-
crofluidic techniques and tissue slice
samples is called “tissue microfluidics”
because it molds the microfluidic ar-
chitectures in accordance with each
particular structure of each specific tis-
sue sample. Thus, microfluidics can be
built around the tissues, following the
tissue structure, or alternatively, the
microfluidics can be adapted to the
specific geometry of particular tissues.
By contrast, the traditional approach is
that microfluidic devices are struc-
tured in accordance with engineering
considerations, while the biological
components in applied devices are
forced to comply with these engineer-
ing presets. 
The proposed principles represent a
paradigm shift in microfluidic technol-
ogy in three important ways: 
• Microfluidic devices are to be directly
integrated with, onto, or around tissue
samples, in contrast to the conven-
tional method of off-chip sample ex-
traction followed by sample insertion
in microfluidic devices. 
• Architectural and operational princi-
ples of microfluidic devices are to be
subordinated to suit specific tissue
structure and needs, in contrast to the
conventional method of building de-
vices according to fluidic function
alone and without regard to tissue
structure. 
• Sample acquisition from tissue is to be
performed on-chip and is to be inte-
grated with the diagnostic measure-
ment within the same device, in con-
trast to the conventional method of
off-chip sample prep and subsequent
insertion into a diagnostic device. A
more advanced form of tissue integra-
tion with microfluidics is tissue encap-
sulation, wherein the sample is com-
pletely encapsulated within a
microfluidic device, to allow for full
surface access. 
The immediate applications of these
approaches lie with diagnostics of tissue
slices and biopsy samples — e.g. for can-
cer — but the approaches would also be
very useful in comparative genomics and
other areas of fundamental research in-
volving heterogeneous tissue samples. 
The approach advocates and utilizes
the bottom-up customization of mi-
crofluidic architectures to biosamples,
in contrast to the traditional top-down
approach of building the architectures
first and then putting the biosamples in-
side. Further, as particular embodiments
of the above principle, novel techniques
of sub-sample selection and isolation are
presented. These techniques would have
wide applicability in fundamental re-
search and biomedical diagnostics. 
In particular, an in situ microfluidic
technique of single-cell isolation, or
multiple single-cell isolations, is de-
scribed, and is performed upon tissue
sections attached to pathology glass
slides. The technique combines the ad-
vantages of preserving the architec-
tural integrity of the tissue section
while allowing flexibility and precision
of cell selection, rapid prototyping,
and enhanced sample purity, while
benefiting from the experience of the
pathologist in the selection process.
The result is a system that would allow
the rapid and reliable biochemical
analysis and diagnosis of pathologic
processes with sensitivity extended
down to the level of even a single cell,
with high levels of confidence in the di-
agnostic determination. 
These techniques would allow the ex-
traction of cells and cell nuclei chosen
for their potentially pathologic origin,
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A process has been developed that can
confer novel properties, such as metal re-
sistance, to a host bacterium. This same
process can also be used to produce
RNAs and peptides that have novel prop-
erties, such as the ability to bind particu-
lar compounds. It is inherent in the
method that the peptide or RNA will be-
have as expected in the target organism.
Plasmid-born mini-gene libraries coding
for either a population of combinatorial
peptides or stable, artificial RNAs carry-
ing random inserts are produced. These
libraries, which have no bias towards any
biological function, are used to trans-
form the organism of interest and to
serve as an initial source of genetic varia-
tion for stress-driven evolution. 
The transformed bacteria are propa-
gated under selective pressure in order
to obtain variants with the desired prop-
erties. The process is highly distinct
from in vitro methods because the vari-
ants are selected in the context of the
cell while it is experiencing stress.
Hence, the selected peptide or RNA will,
by definition, work as expected in the
target cell as the cell adapts to its pres-
ence during the selection process. Once
the novel gene, which produces the
sought phenotype, is obtained, it can be
transferred to the main genome to in-
crease the genetic stability in the organ-
ism. Alternatively, the cell line can be
used to produce novel RNAs or peptides
with selectable properties in large quan-
tity for separate purposes. The system al-
lows for easy, large-scale purification of
the RNAs or peptide products.
Stress-Driven Selection of Novel Phenotypes
A methodology allows the experimental design of novel peptides and RNAs 
that have desired properties.
Lyndon B. Johnson Space Center, Houston, Texas
The aim of tissue engineering (TE) is
to restore tissue and organ functions
with minimal host rejection. TE is seen
as a future solution to solve the crisis of
donor organs for transplant, which faces
a shortage expected only to increase in
the future. In this innovation, a flexible
and configurable scaffold has been con-
ceived that mechanically stresses cells
that are seeded on it, stimulating them
to increased growth. 
The influence of mechanical stress/
loading on cell growth has been ob-
served on all forms of cells. For exam-
ple, for cartilages, studies in animals, tis-
sue explants, and engineered tissue
scaffolds have all shown that cartilage
cells (chondrocytes) modify their extra-
cellular matrix in response to loading.
The chondrocyte EMC production re-
sponse to dynamics of the physical envi-
ronment (in vivo cartilage develop-
ment) illustrates a clear benefit (better
growth) when stressed. It has been
shown that static and dynamic compres-
sion regulates PRG4 biosynthesis by car-
tilage explants. 
Mechanical tissue stimulation is bene-
ficial and (flexible) scaffolds with mov-
able components, which are able to in-
duce mechanical stimulation, offer
advantages over the fixed, rigid scaffold
design. In addition to improved cell
growth from physical/mechanical stimu-
lation, additional benefits include the
ability to increase in size while preserv-
ing shape, or changing shape.
By making scaffolds flexible, allowing
relative movement between their com-
ponents, adding sensing (e.g., for de-
tecting response of cells to drug release
and to mechanical actions), building
controls for drug release and move-
ment, and building even simple algo-
rithms for mapping sensing to action,
these structures can actually be made
into biocompatible and biodegradable
robots. Treating them as robots is a per-
spective shift that may offer advantages
in the design and exploitation of these
structures of the future.
This work was done by Adrian Stoica of Cal-
tech for NASA’s Jet Propulsion Laboratory. For
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Robotic Scaffolds for Tissue Engineering and Organ Growth 
Biocompatible and biodegradable smart scaffolds could reconfigure their shape and size to
accommodate organ development. 
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e.g. cancer. The chief advantages of the
proposed methods are their speed, ease,
reliability, and capacity to select individ-
ual cells from a tissue slice population
with a higher degree of purity and speci-
ficity. The result is the extracted DNA
can be biochemically analyzed with a
higher degree of diagnostic accuracy, as
the isolated sub-sample would not be di-
luted by unwanted material from the
ambient tissue. In comparison to other
techniques, the proposed methods
would combine high specificity with
high speed. 
This work was done by Lawrence A. Wade
of Caltech and Emil P. Kartalov, Darryl Shi-
bata, and Clive Taylor of the University of
Southern California for NASA’s Jet Propulsion
Laboratory. Further information is contained
in a TSP (see page 1).
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